Sino Biological GPRC5D Protein Human Recombinant Biotinylated anti-gprc5d

纯度> 95 % as determined by SEC-HPLC.
内毒素< 1.0 EU per μg of the protein as determined by the LAL method
生物活性Immobilized Biotinylated Human GPRC5D-VLP (Full Length) Protein (Cat: 24447-HNAH-B) at 5 μg/mL (100 μL/well) on streptavidin precoated (2 μg/well) can bind Anti-Human GPRC5D Antibody, Human IgG1, the EC50 is 4-12ng/mL.
蛋白构建A DNA sequence encoding the human GPRC5D (Q9NZD1-1) (Met1-Val345) was expressed.
表达宿主HEK293 Cells
种属Human
预测 N 端Met 1
分子量The recombinant human GPRC5D consists of 345 amino acids and predicts a molecular mass of 38.80 kDa.
缓冲液Supplied as sterile solution in 50mM HEPES, 150mM NaCI, 10% Trehalose, pH 7.2.
Please contact us for any concerns or special requirements.
Please refer to the specific buffer information in the hard copy of CoA.
运输方式It is supplied and shipped as liquid with dry ice.
稳定性 & 储存条件Samples are stable for up to twelve months from date of receipt at -70℃. Store it under sterile conditions at -70℃ or lower. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.



图2
GPRC5D Protein, Human, Recombinant, Biotinylated, HPLC-verified: 别称
GPRC5D Protein, Human
GPRC5D 背景信息
Orphan G-protein-coupled receptor family C group 5 member D (GPRC5D) has seven transmembrane segments forming the core of the receptor, as well as an intracellular C-tail and an extracellular N-terminal domain. GPRC5D is highly and selectively expressed on the surface of CD138+ multiple myeloma (MM) cells, whereas in normal tissues, a much lower expression is limited to plasma cells and certain hard keratinizing tissues. This makes GPRC5D a promising marker for monitoring tumor load and a target antigen for MM-specific T cell-engaging therapies such as bispecific antibodies and CAR-T cells.
参考文献
1. Eric L. Smith, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci. Transl. Med. 2019. 2. Christie, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv 2021. 3. Tatsushi Kodama, et al. Anti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody for the Treatment of Multiple Myeloma. Mol Cancer Ther 1 September 2019.